Payment overview · 2025
General Payments
$614.33
13 reported records · 7 companies
Healthcare provider profile · identity verified
Jacob V George, MD
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1679674717
Verified facts
What the public records show
CMS Open Payments records show Jacob V George, MD received $614.33 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $337.38 | 54.9% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $154.13 | 25.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $29.21 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.78 | 4.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.00 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.10 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.73 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $614.33 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.42 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.96 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 259 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 217 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
259 | 58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
162 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
124 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 680 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 616 | 178 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 482 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 456 | 133 |
| Gabapentin | Gabapentin | 449 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 108 |
| Metformin Hcl | Metformin Hcl | 409 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 394 | 115 |
| Losartan Potassium | Losartan Potassium | 343 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 320 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 97 |
| Januvia | Sitagliptin Phosphate | 284 | 50 |
| Famotidine | Famotidine | 272 | 77 |
| Jardiance | Empagliflozin | 259 | 58 |
| Raloxifene Hcl | Raloxifene Hcl | 254 | 67 |
| Meclizine Hcl | Meclizine Hcl | 252 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 235 | 90 |
| Ozempic | Semaglutide | 217 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 71 |
| Linzess | Linaclotide | 208 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 203 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 45 |
| Mirtazapine | Mirtazapine | 197 | 50 |
| Alendronate Sodium | Alendronate Sodium | 190 | 58 |
| Montelukast Sodium | Montelukast Sodium | 184 | 60 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 183 | 44 |
| Ibuprofen | Ibuprofen | 181 | 74 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 180 | 50 |
| Lisinopril | Lisinopril | 175 | 53 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 170 | 27 |
| Synjardy | Empagliflozin/Metformin Hcl | 162 | 25 |
| Naproxen | Naproxen | 156 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 45 |
| Tramadol Hcl | Tramadol Hcl | 149 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 144 | 40 |
| Trulicity | Dulaglutide | 138 | 19 |
| Celecoxib | Celecoxib | 137 | 44 |
| Meloxicam | Meloxicam | 135 | 52 |
| Simvastatin | Simvastatin | 134 | 38 |
| Ammonium Lactate | Ammonium Lactate | 127 | 47 |
| Pregabalin | Pregabalin | 125 | 21 |
| Rybelsus | Semaglutide | 124 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 120 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 33 |
| Mounjaro | Tirzepatide | 118 | 19 |
| Lidocaine | Lidocaine | 113 | 28 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 107 | 23 |
| Eliquis | Apixaban | 106 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 97 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 26 |
| Irbesartan | Irbesartan | 95 | 28 |
| Vascepa | Icosapent Ethyl | 95 | 27 |
| Donepezil Hcl | Donepezil Hcl | 94 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 25 |
| Ramipril | Ramipril | 94 | 28 |
| Finasteride | Finasteride | 91 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 87 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 87 | 22 |
| Furosemide | Furosemide | 85 | 27 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 79 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 79 | 28 |
| Cilostazol | Cilostazol | 77 | 26 |
| Mometasone Furoate | Mometasone Furoate | 77 | 35 |
| Promethazine Hcl | Promethazine Hcl | 76 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 34 |
| Farxiga | Dapagliflozin Propanediol | 73 | 16 |
| Azithromycin | Azithromycin | 72 | 58 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 70 | 25 |
| Enalapril Maleate | Enalapril Maleate | 68 | 19 |
| Ibu | Ibuprofen | 65 | 25 |
| Labetalol Hcl | Labetalol Hcl | 62 | 14 |
| Carvedilol | Carvedilol | 61 | 19 |
| Flurbiprofen | Flurbiprofen | 61 | 18 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 61 | 16 |
| Estradiol | Estradiol | 60 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 59 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 59 | 12 |
| Etodolac | Etodolac | 57 | 21 |
| Procto-Med Hc | Hydrocortisone | 57 | 15 |
| Valacyclovir | Valacyclovir Hcl | 57 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 14 |
| Sertraline Hcl | Sertraline Hcl | 53 | 15 |
| Buspirone Hcl | Buspirone Hcl | 50 | 16 |
| Hydrocortisone | Hydrocortisone | 50 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Ketoconazole | Ketoconazole | 49 | 15 |
| Valsartan | Valsartan | 47 | 15 |
| Azelastine Hcl | Azelastine Hcl | 46 | 13 |
| Nifedipine Er | Nifedipine | 46 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 13 |
| Alprazolam | Alprazolam | 44 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 44 | suppressed |
| Brilinta | Ticagrelor | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 15 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | 11 |
| Prolia | Denosumab | 36 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | 11 |
| Cyclosporine | Cyclosporine | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | 19 |
| Zerviate | Cetirizine Hcl | 34 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 16 |
| Atenolol | Atenolol | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | 11 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Piroxicam | Piroxicam | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Fluocinonide | Fluocinonide | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Nystatin | Nystatin | 26 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Dexilant | Dexlansoprazole | 22 | 14 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 21 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | 13 |
| Naproxen Sodium Cr | Naproxen Sodium | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alrex | Loteprednol Etabonate | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Rectiv | Nitroglycerin | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $614.33 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, IBSRELA, JARDIANCE, Ozempic, REXULTI, Yeztugo | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error